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Abstract
Purpose: Serotonin and the serotonin transporter have been implicated in the development of pulmonary hypertension
(PH). Selective serotonin reuptake inhibitors (SSRIs) may have a role in PH treatment, but the effects of SSRI use on right
ventricular (RV) structure and function are unknown. We hypothesized that SSRI use would be associated with RV
morphology in a large cohort without cardiovascular disease (N=4114).
Methods: SSRI use was determined by medication inventory during the Multi-Ethnic Study of Atherosclerosis baseline
examination. RV measures were assessed via cardiac magnetic resonance imaging. The cross-sectional relationship between
SSRI use and each RV measure was assessed using multivariable linear regression; analyses for RV mass and end-diastolic
volume (RVEDV) were stratified by sex.
Results: After adjustment for multiple covariates including depression and left ventricular measures, SSRI use was
associated with larger RV stroke volume (RVSV) (2.75 mL, 95% confidence interval [CI] 0.48–5.02 mL, p=0.02). Among men
only, SSRI use was associated with greater RV mass (1.08 g, 95% CI 0.19–1.97 g, p=0.02) and larger RVEDV (7.71 mL, 95%
3.02–12.40 mL, p=0.001). SSRI use may have been associated with larger RVEDV among women and larger RV end-systolic
volume in both sexes.
Conclusions: SSRI use was associated with higher RVSV in cardiovascular disease-free individuals and, among men, greater
RV mass and larger RVEDV. The effects of SSRI use in patients with (or at risk for) RV dysfunction and the role of sex in
modifying this relationship warrant further study.
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Introduction
Serotonin, a potent vasoconstrictor, and the serotonin
transporter (5-HTT) have mitogenic effects on pulmonary artery
smooth muscle cells (PA-SMCs) [1]. Serotonin has been
implicated in the development of pulmonary arterial hyperten-
sion (PAH) since anorexigens (which activate 5-HTT) were noted
to increase the risk of PAH [2]. Some patients with PAH may
have elevated levels of serotonin which persist beyond treatment
[3,4,5]. 5-HTT overexpression leads to the development of
pulmonary hypertension (PH) and PA-SMC hyperplasia, and 5-
HTT polymorphisms have been associated with disease devel-
opment [1,6,7,8]. Selective serotonin reuptake inhibitors (SSRIs)
inhibit 5-HTT, making them appealing therapies for study in
pulmonary vascular disease.
SSRIs protect against pulmonary vascular changes and right
ventricle (RV) hypertrophy in animal models of pulmonary
vascular disease [9,10,11]. Human PA-SMCs demonstrate
attenuated growth when exposed to SSRIs [1,12]. We have
observed a possible lower risk of death in PAH patients treated
with SSRIs compared to those not treated [13]. More recently,
Shah et al. found SSRI use was associated with both a decreased
incidence of PAH and reduced mortality in patients with PAH
[14]. A randomized clinical trial to evaluate the efficacy of
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30480escitalopram in patients with PAH was recently completed
(NCT00190333).
While there is compelling evidence that SSRIs may be a
promising therapy in pulmonary vascular disease, the effects of
SSRI use on RV function, an important determinant of outcome
in PH and PAH, are unknown. Studying the impact of potential
PH therapies on RV structure and function in individuals without
clinical cardiovascular disease (or in those with subclinical disease)
may inform the study of novel therapeutics in patients with
pulmonary vascular disease and RV failure. We examined the
cross-sectional association of SSRI use with RV structure and
function assessed by cardiac magnetic resonance imaging (MRI) in
a large cohort without clinical cardiovascular disease. We
hypothesized that SSRI use would be associated with larger RV
stroke volume (RVSV) and higher RV ejection fraction (RVEF)
and lower RV mass, end-diastolic volume (RVEDV), and end-
systolic volume (RVESV).
Methods
Study Sample
The protocols of the Multi-Ethnic Study of Atherosclerosis
(MESA) and studies described herein were approved by the
Institutional Review Boards of all institutions (Columbia Univer-
sity, New York; Johns Hopkins University, Baltimore; Northwest-
ern University, Chicago; University of California, Los Angeles;
University of Minnesota, Twin Cities; Wake Forest University,
Winston-Salem) and the National Heart Lung and Blood Institute.
Written informed consent was obtained from all participants.
MESA is a multicenter prospective cohort study to investigate
subclinical cardiovascular disease in Caucasians, African-Ameri-
cans, Hispanics, and Chinese [15]. In 2000–2002, MESA
recruited 6,814 participants aged 45–84 years old from six U.S.
communities: Forsyth County, NC; Northern Manhattan and the
Bronx, NY; Baltimore City and Baltimore County, MD; St. Paul,
MN; Chicago, IL; and Los Angeles, CA. Exclusion criteria
included clinical cardiovascular disease, weight .300 lbs, preg-
nancy, or impediment to long-term participation. The presence of
clinical cardiovascular disease was determined at screening by
questionnaire. Participants were excluded if they answered ‘‘yes’’
to having been diagnosed by a physician with heart attack, stroke,
transient ischemic attack, heart failure, angina, current atrial
fibrillation, and/or to having undergone any prior cardiovascular
procedure. The MESA-Right Ventricle Study measured RV
morphology in 4204 participants with interpretable MRIs. MESA-
Right Ventricle participants were sampled without regard to
demographics, anthropometrics, or other clinical variables.
Cardiac Magnetic Resonance Imaging Measures
The cardiac MRI protocol has been described elsewhere [16].
All imaging was performed on 1.5 T magnets with a 4-element
phased-array surface coil positioned anteriorly and posteriorly and
electrocardiographic gating. Imaging consisted of fast gradient
echo cine images with temporal resolution #50 ms.
Methods for interpretation of left ventricle (LV) and RV
parameters have been previously reported [16,17]. Briefly, RV
image analysis was performed by two independent analysts on
Windows workstations using QMASS software (v4.2, Medis, the
Netherlands). The endocardial and epicardial borders of the RV
were traced manually on short axis cine images at the end-diastolic
and end-systolic phase. Papillary muscles and trabeculae were
included in the RV volumes and excluded from RV mass [18].
RVEDV and RVESV were calculated using Simpson’s rule by
summation of areas on each slice multiplied by the sum of slice
thickness and image gap. RV mass was determined at end-diastole
as the difference between end-diastolic epicardial and endocardial
volumes multiplied by the specific gravity of the heart (1.05 g/cm
3)
[16]. RVSV was calculated by subtracting RVESV from RVEDV.
RVEF was calculated by dividing RVSV by RVEDV. The intra-
reader intraclass correlation coefficient (ICC) from random,
blinded re-reads of 229 scans for RV mass was 0.94 and for 230
scans was 0.99, 0.95, and 0.89 for RVEDV, RVESV, and RVEF,
respectively. The intra-reader ICC was 0.96 for RVSV. The inter-
reader ICC from random, blinded re-reads of 240 scans for RV
mass, RVEDV, RVESV, and RVEF was 0.89, 0.96, 0.94 and
0.80, respectively. The inter-reader ICC for RVSV was 0.93.
Selective Serotonin Reuptake Inhibitor Use
A validated medication inventory was used to assess SSRI use
during the baseline exam [19]. Participants were asked to bring all
containers for medications used during the two weeks prior to the
baseline visit. Interviewers transcribed all current medication
names, strengths, and dosages from medication bottles. Partici-
pants were queried about actual medication intake and interview-
ers recorded the average number of pills taken. In circumstances
where no medication was taken, the interviewer coded medication
intake as ‘‘0’’. Total duration of SSRI use (beyond the two weeks
prior to the baseline visit) was not available. Fluoxetine,
fluvoxamine, paroxetine, and sertraline were classified as high-
affinity SSRIs (dissociation constant [Kd],1 nmol) and citalopram
as a medium-affinity SSRI ([Kd].1 nmol) for sub-group analyses.
Other Covariates
Race/ethnicity was self-reported during the baseline exam
according to 2000 US Census criteria as race (Caucasian, African-
American, etc) and ethnicity (Hispanic or non-Hispanic). Standard
questionnaires were used to ascertain smoking status and level of
education. Medication use was ascertained by medication
inventory [19]. A small number of participants taking anorexigens
(N=13) were excluded from the study sample. Height was
measured to the nearest 0.1 cm with the participant in stocking
feet and weight was measured to the nearest pound with the
participant in light clothing using a balanced scale. Resting blood
pressure was measured using the Dinamap Monitor PRO 100
(Critikon, Tampa, FL) automated oscillometric device. Hyperten-
sion was defined as systolic blood pressure $140 mm Hg, diastolic
blood pressure $90 mm Hg or current use of anti-hypertension
medication. Fasting blood samples were drawn and sent to a
central laboratory for measurement of lipids. The presence of
depressive symptoms was assessed during the baseline examination
using the Center for Epidemiologic Studies Depression Scale
(CES-D) [20]. Depression was defined as a CES-D score $16
points [20].
Statistical Analysis
Continuous variables were expressed as means and standard
deviations. Categorical variables were expressed as %. Indepen-
dent sample t tests were used to compare continuous variables and
chi-square tests were used to compare categorical variables in
SSRI users and non-users. Multivariate linear regression was used
to assess the relationship of SSRI use with each RV parameter.
Limited models included age, sex, race/ethnicity, height, weight,
and level of education. Adjustment for height and weight avoided
the assumptions made in indexing the RV measures to parameters
of body size (e.g., body surface area), while accounting for
differences in body size between participants.
We selected covariates which were possibly related to either
SSRI use or RV morphology. We retained covariates in the
SSRIs and the Right Ventricle
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estimate for SSRI use and any of the RV measures. Adjusted
models included age, sex, race/ethnicity, height, weight, level of
education, depression (CES-D $16), smoking (status and pack-
years), hypertension, systolic and diastolic blood pressure,
cholesterol, low-density lipoprotein levels, triglycerides, and statin
use. Possible covariates that were considered but not adjusted for
(based on this criterion) included waist circumference, diabetes
mellitus, impaired glucose tolerance, antihypertensive medication
use, high density lipoprotein levels, serum sex hormone levels, and
intentional exercise. While depression (CES-D $16 points) did not
significantly confound the relationship between SSRI use and RV
measures by this criterion, this covariate was forced into the
adjusted models. Finally, respective LV measures were added to
the adjusted models to account for the contribution of LV
abnormalities to RV changes (e.g., increased LV mass causing
pulmonary venous hypertension leading to increased RV mass), to
account for body size differences, and to examine RV-specific
associations. RVSV was not adjusted for LV stroke volume
considering the significant inter-dependence of these measures.
Statistical significance was defined as P,0.05. Analyses were
performed using STATA 10.0 (StataCorp, College Station, TX).
Results
MESA enrolled 6814 participants of whom 5098 had available
cardiac MRI and 5004 had scans interpretable for LV measures
(Figure 1). Of these, 4634 were selected, and 4204 (the a priori
sample size for MESA-Right Ventricle) were successfully inter-
preted for RV measures. We excluded participants with a self-
reported (N=11) or unknown (N=2) history of anorexigen use
and those with missing covariate data (N=77). The final study
sample consisted of 4114 participants.
The characteristics of the study sample and excluded partici-
pants are shown in Table 1. Overall, the study sample was similar
to those excluded. In the study sample, 203 (4.9%) were using
SSRIs. Among SSRI users, 182 (89.7%) used high-affinity agents.
Characteristics of SSRI users and non-users are shown in Table 2.
SSRI users were more likely to be female, Caucasian, and better
educated compared to non-users. The prevalence of hypertension
and smoking was similar between the two groups, while SSRI
users had higher mean cholesterol and triglyceride levels, were
more likely to be taking statins, and were more likely to have been
treated for diabetes. Not surprisingly, SSRI users had higher mean
CES-D scores and more commonly had depression. There were
significant interactions between SSRI use and sex in terms of RV
mass (p for interaction=0.02) and RVEDV (p for interac-
tion=0.01). Analyses for these parameters are shown stratified
by sex. Table 3 compares characteristics of the study sample by
sex. Women tended to be less well educated, never smokers, and
had a higher prevalence of depression. While men tended to be
taller and weigh more, body mass index (BMI) was similar between
the sexes.
Selective Serotonin Reuptake Inhibitor Use
SSRI use was associated with a 2.75 mL (3.2%) higher RVSV
after adjustment for all covariates (95% confidence interval [CI]
0.48–5.02 mL, p=0.02) (Table 4). There was no association
between SSRI use and RVEF. In men, SSRI use was associated
with a 4.7% higher RV mass after adjustment for all covariates
including LV mass (1.08 g, 95% CI 0.19–1.97 g, p=0.02), but
there was no association in women. Also, there was a stronger
association between SSRI use and larger RVEDV (5.5% larger)
among men than among women (1.7% larger). While not
statistically significant, SSRI use may have been associated with
larger RVESV after adjustment for LV end-systolic volume.
After limiting our analysis to those using high-affinity agents
(N=182, 89.7% of SSRI users), we found similar associations with
RVSV and no association with RVEF (Table 5). As with the total
study sample, there were significant interactions between SSRI use
and sex for RV mass (p for interaction=0.02) and RVEDV (p for
interaction=0.01). In men, high-affinity SSRI use was associated
with greater RV mass even after adjustment for LV mass (1.30 g,
95% CI 0.35–2.24 g, p=0.01), but there was no association in
women. The association of high-affinity SSRI use with larger
Figure 1. Study sample. MESA: Multi-Ethnic Study of Atherosclerosis; MRI: magnetic resonance imaging; LV: left ventricle; RV: right ventricle.
doi:10.1371/journal.pone.0030480.g001
SSRIs and the Right Ventricle
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Study Sample Excluded
Number 4114 2700
Demographics
Age, years 61.5610.1 63.2610.4
Male, % 47.6 46.5
Race/ethnicity, % Caucasian 39.4 37.1
African-American 26.2 30.2
Hispanic 21.9 22.0
Chinese 12.5 10.7
Education, % ,High school 16.3 20.7
High school 18.4 17.9
, College, (.high school) 28.5 28.6
$College 36.8 32.8
Anthropometrics
Height, cm 166.469.9 166.3610.2
Weight, kg 77.5616.2 80.8618.8
Body mass index, kg/m
2 27.965.0 29.166.1
Comorbid Factors
Hypertension, % 42.9 48.0
Systolic blood pressure, mm Hg 125.5621.0 128.3622.1
Diastolic blood pressure, mm Hg 71.9610.2 72.0610.4
Diabetes mellitus, % Normal 75.2 71.0
Impaired fasting glucose 13.2 14.8
Untreated diabetes 2.4 3.0
Treated diabetes 9.2 11.3
Total cholesterol, mg/dl 194.4635.0 193.8636.8
Low-density lipoprotein, mg/dl 117.4630.8 116.9632.4
Triglycerides, mg/dl 130.8684.9 132.8694.5
Statin use, % 14.7 15.1
Smoking Status Never-smoker, % 52.1 47.6
Former smoker, % 35.4 38.5
Current smoker, % 12.5 13.9
Pack years, among ever-smokers 10.9622.8 12.2621.4
Depression and Antidepressant Use
Center for Epidemiologic Studies Depression Scale
(CES-D), points
7.467.4 7.967.8
Depression (CES-D $16), % 12.4 14.9
Antidepressant use, % Single agent, % 8.8 8.1
Combination (.1 agent), % 0.3 0.1
Selective serotonin reuptake inhibitors, % 4.9 4.5
Medium affinity* 0.5 0.8
High affinity{ 4.4 3.7
Selective-norepinephrine reuptake inhibitors, % 0.6 0.6
Tricyclic antidepressants, % 1.3 1.4
Other{,% 2.0 1.6
Data shown as mean 6 standard deviation or %. Percentages may not add to one because of rounding.
*Citalopram.
{Fluoxetine, fluvoxamine, paroxetine, and sertraline.
{Includes atypical (bupropion), monoamine oxidase inhibitors, tetracyclic (mirtazapine), and serotonin antagonist and reuptake inhibitor (trazodone and nefazodone)
antidepressants.
doi:10.1371/journal.pone.0030480.t001
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SSRI Users SSRI Non-users P value
Number 203 3911
Demographics
Age, years 60.469.9 61.6610.1 0.11
Male, % 31.0 48.4 ,0.001
Race/ethnicity, % ,0.001
Caucasian 64.0 38.1
African-American 11.8 27.0
Hispanic 19.2 22.1
Chinese 4.9 12.9
Education, % 0.06
,High school 9.9 16.6
High school 17.7 18.5
, College, (. high school) 30.5 28.4
$College 41.9 36.6
Anthropometrics
Height, cm 164.968.9 166.5610.0 0.03
Weight, kg 77.2615.6 77.5616.2 0.76
Body mass index, kg/m
2 28.365.2 27.865.0 0.20
Comorbid Factors
Hypertension, % 42.9 42.9 1.00
Systolic blood pressure, mm Hg 124.7619.8 125.5621.1 0.57
Diastolic blood pressure, mm Hg 70.069.8 72.0610.2 0.01
Diabetes mellitus, % 0.02
Normal 77.8 75.0
Impaired fasting glucose 8.9 13.4
Untreated diabetes 0.5 2.5
Treated diabetes 12.8 9.0
Total cholesterol, mg/dl 200.0634.4 194.1635.0 0.02
Low-density lipoprotein, mg/dl 118.1631.0 117.4630.8 0.73
Triglycerides, mg/dl 141.3678.5 130.3685.2 0.07
Statin use, % 22.2 14.3 ,0.01
Smoking Status 0.33
Never-smoker, % 47.3 52.4
Former smoker, % 39.9 35.2
Current smoker, % 12.8 12.5
Pack years, among ever-smokers 13.7623.2 10.8622.7 0.07
Depression
Center for Epidemiologic Studies Depression
Scale (CES-D), points
10.869.5 7.267.3 ,0.01
Depression (CES-D $16), % 24.1 11.8 ,0.001
RV measures RVSV, mL 87.9621.2 86.8620.6 0.46
RVEF, % 71.066.0 70.466.5 0.22
RV mass, g 21.164.5 21.064.5 0.91
RVEDV, mL 124.4631.1 124.1630.9 0.91
RVESV, mL 36.5613.6 37.3614.3 0.43
Data shown as mean 6 standard deviation or %. Percentages may not add to one because of rounding.
doi:10.1371/journal.pone.0030480.t002
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(and not present after adjustment for LV end-diastolic volume).
Discussion
SSRI use was associated with higher RVSV in men and women
and with greater RV mass in men only. SSRI use may have been
associated with larger RVESV in both sexes and was more strongly
associated with larger RVEDV in men than in women. There was
no association between SSRI use and RVEF. To our knowledge,
this is the only study of SSRI use and RV morphology in humans.
Increased stroke volume and end-diastolic volume without a
change in ejection fraction is seen in the LV in athletes, and even
in the RV in MESA participants who report higher levels of
exercise [21,22]. This suggests that the SSRI-associated changes
may be adaptive. Animal models suggest that RV adaptation to
exercise may not only outstrip LV changes, but that RV eccentric
hypertrophy leads to an increase in capillary networks and oxygen
Table 3. Characteristics of men and women included in the study sample.
Men Women
Number 1957 2157
Demographics
Age, years 61.5610.1 61.5610.1
Race/ethnicity, % Caucasian 38.6 40.1
African-American 25.2 27.1
Hispanic 23.5 20.6
Chinese 12.8 12.2
Education, % , High school 15.5 17.0
High school 15.7 20.9
, College, (. high school) 26.0 30.7
$ College 42.8 31.4
Anthropometrics
Height, cm 173.467.7 160.067.0
Weight, kg 83.1614.8 72.4615.8
Body mass index, kg/m
2 27.564.1 28.265.6
Comorbid Factors
Hypertension, % 40.9 44.6
Systolic blood pressure, mm Hg 125.1618.9 125.8622.7
Diastolic blood pressure, mm Hg 74.969.3 69.1610.2
Diabetes mellitus, % Normal 71.6 78.4
Impaired fasting glucose 15.7 10.9
Untreated diabetes 2.9 2.0
Treated diabetes 9.8 8.7
Total cholesterol, mg/dl 188.1633.8 200.2635.1
Low-density lipoprotein, mg/dl 116.9630.4 117.8631.2
Triglycerides, mg/dl 133.6686.7 128.3683.2
Statin use, % 13.8 15.5
Smoking Status Never-smoker, % 42.6 60.8
Former smoker, % 43.4 28.1
Current smoker, % 14.1 11.1
Pack years, among ever-smokers 14.3627.6 7.9616.7
Depression
Center for Epidemiologic Studies Depression Scale
(CES-D), points
6.366.5 8.468.0
Depression (CES-D $16), % 8.0 16.3
RV measures RVSV, % 95.9620.7 78.6616.7
RVEF, % 68.266.2 72.566.0
RV mass, g 23.164.4 19.263.6
RVEDV, mL 140.9629.7 108.9623.2
RVESV, mL 45.1614.1 30.3610.2
Data shown as mean 6 standard deviation or %. Percentages may not add to one because of rounding.
doi:10.1371/journal.pone.0030480.t003
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ventricular response to pressure loading has been well-described
in the LV, in pulmonary vascular disease the spectrum of RV
changes (from adaptive to maladaptive) is less well understood
[25]. In animals with moderate PH, exercise results in enhanced
capillarization (implying compensation) whereas in those with
progressive disease increased RV diameter and wall stress develops
(implying maladaptation), albeit with a similar degree of
hypertrophy in both moderate and progressive PH [26]. Several
small observational and a single randomized trial have examined
changes in RV morphology with therapy in PAH patients at
advanced stages of disease (i.e., predominantly World Health
Organization functional class II/III) and shown decrements in RV
mass and volumes with improved systolic function [27,28,29].
While we postulate that the SSRI-related associations with RV
mass and volumes seen here may be adaptive in health or in
subclinical disease, the clinical impact of SSRI-related changes in
patients with advanced pulmonary vascular disease is not known.
In our study, the association between SSRI use and greater RV
mass (in men only) persisted after adjustment for LV mass,
implying that 5-HTT inhibition may not only uniquely impact the
RV but that these effects may vary by sex. Endurance training and
subsequent ventricular hypertrophy have been correlated with
increased aerobic capacity in athletes, and interestingly men may
have a more pronounced response as compared to women
[22,30,31]. In experimental PH, 5-HTT inhibition leads to
reductions in pulmonary artery pressure and subsequent decreases
in RV mass [10]. However, our observations suggest that in
normal individuals presumably without significant pulmonary
vascular disease, SSRI use is associated with increased RV mass.
Although not feasible in a disease-free cohort of over 4000
individuals, hemodynamic data from right heart catheterization
could have elucidated the association between SSRI use and
pulmonary vascular function.
We have recently shown that serum sex hormone levels are
associated with RV morphology in a sex-specific manner [32].
While sex hormones do not appear to confound the associations
seen here, sex is known to play a role in serotonin-stimulated
platelet aggregation and kinetics and 5-HTT is differentially
regulated in men and women [33,34,35]. Additionally, RV
structure and function vary by sex in both health and disease,
with men having greater RV mass and volumes but lower RVEF
than women, suggesting SSRIs may differentially impact mor-
phology depending on sex [36,37]. While adjustment for sex
hormone levels did not change effect estimates in our study, it is
certainly possible that hormones may underpin different morpho-
logic changes in men and women.
Animal studies of acute and chronic left heart failure have
implicated serotonin as an important regulator of cardiac
hypertrophy [38,39]. In young animals, knock-out of serotonin
receptors results in dilated cardiomyopathy, suggesting an
important role of serotonin in the developing heart. Receptor
overexpression in adult animals, however, leads to maladaptive
hypertrophy [40]. Epidemiologic studies suggest that the use of
SSRIs in patients with ischemic heart disease may be beneficial
[41,42,43,44]. In a randomized clinical trial of SSRIs to treat
patients with major depressive disorder and acute coronary
syndrome, SSRI use did not affect LV ejection fraction, but did
lower risk of adverse cardiovascular events, possibly by inhibiting
platelet activation and preserving endothelial function [45,46]. A
Table 4. Associations between SSRI use and RV measures in limited and adjusted models, stratified by sex for RV mass and RVEDV.
Beta (95% CI) P value
Men
Beta (95% CI) P value
Women
Beta (95%CI) P value
RVSV, mL
Limited* 2.54 (0.26–4.83) 0.03 – – – –
Adjusted{ 2.75 (0.48–5.02) 0.02 – – – –
RVEF, %
Limited 0.02 (20.84–0.88) 0.97 – – – –
Adjusted 20.14 (21.01–0.72) 0.74 – – – –
Adjusted + LVEF 20.23 (21.03–0.57) 0.57 – – – –
RV mass, g
Limited – – 0.89 (20.05–1.83) 0.06 0.05 (20.45–0.54) 0.86
Adjusted – – 1.01 (0.06–1.96) 0.04 0.13 (20.37–0.63) 0.61
Adjusted + LV mass – – 1.08 (0.19–1.97) 0.02 0.06 (20.41–0.53) 0.80
RVEDV, mL
Limited – – 4.99 (21.30–11.28) 0.12 2.55 (20.55–5.65) 0.11
Adjusted – – 5.80 (20.54–12.14) 0.07 3.24 (0.14–6.34) 0.04
Adjusted + LVEDV – – 7.71 (3.02–12.40) 0.001 1.84 (20.47–4.15) 0.12
RVESV, mL
Limited 0.77 (20.76–2.31) 0.32 – – – –
Adjusted 1.15 (20.39–2.70) 0.14 – – – –
Adjusted + LVESV 1.21 (21.18–2.59) 0.09 – – – –
*Adjusted for age, sex, race/ethnicity, height, weight, and level of education.
{Adjusted for age, sex, race/ethnicity, height, weight, level of education, depression (Center for Epidemiologic Studies.
Depression-Scale (CES-D) $16), smoking (status and pack-years), hypertension, systolic and diastolic blood pressure, cholesterol, low-density lipoprotein levels,
triglycerides, and statin use.
doi:10.1371/journal.pone.0030480.t004
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congestive heart failure (CHF) showed no difference in composite
cardiovascular events between intervention and control arms [47].
A larger trial of escitalopram in CHF is on-going and includes sub-
studies to investigate escitalopram’s effects on platelet function and
endothelial vasoreactivity [48].
The impact of serotonin and its pathways on RV structure and
function has not been extensively studied. In animals, serotonin
causes protein oxidation in the RV (but not in the LV) and
treatment with SSRIs prevents RV hypertrophy and lowers RV
weight in PH models [11,49,50,51]. Treatment with SSRIs
suppresses PA-SMC proliferation but also increases pulmonary
arterial cellular apoptosis, which may or may not be beneficial in
the RV [52]. While serotonin released from pulmonary endothe-
lial cells stimulates growth of PA-SMCs, it is unknown how cardiac
endothelial function and myocytes might be affected by these
paracrine effects [12]. Finally, it is difficult to reconcile the
potential benefit of SSRIs in PAH with the observational evidence
that maternal SSRI use may increase the risk of persistent
pulmonary hypertension of the newborn in infants [53].
Our study has several limitations. While the effect sizes seem
small (ranging from 3.2% to 5.5%), they are comparable to those
seen in the LV related to active smoking and diabetes mellitus and
in the RV related to physical activity (e.g., a 7% increase in
RVEDV and a 5% increase in RV mass with higher levels of
physical activity), but more subtle than the associations we have
shown in the RV related to obesity [54,55,56]. A few small studies
have shown similar magnitudes of effect on RV tissue Doppler
imaging [57,58,59]. In severe PAH, long-term intravenous
epoprostenol improves RVSV by approximately 12% [28]. In a
normal individual, similar or smaller differences (in absolute or
relative terms) may therefore have important physiologic effects.
As our study is observational, no conclusions can be drawn about a
causal role of SSRI use in RV morphology. Confounding by
indication is possible, although it is unlikely that SSRIs were
differentially prescribed based on subclinical differences in RV
structure and function. Certain covariates may have influenced
both SSRI use and RV measures, leading to unmeasured or
residual confounding. While recall bias could be present, the
medication inventory method utilized has been validated and
medication use was assessed before the RV data were available,
making differential recall based on RV morphology unlikely [19].
Unfortunately, duration of SSRI use was not assessed but would
have allowed for further quantification of the observed associa-
tions. Some participants could have been on long-term SSRIs,
while others for only a short period of time (a minimum of two
weeks). However, such misclassification would likely bias to the
null (e.g., a participant taking an SSRI for a few months before the
baseline study visit would be unlikely to experience RV effects, yet
would still be classified as ‘‘exposed’’).
We have shown that SSRI use is associated with higher RVSV,
larger RVEDV and greater RV mass (in men) in cardiovascular
disease-free participants. Studies of SSRIs in patients with or at
risk for pulmonary vascular disease should include specific
assessments of RV effects and sex may prove important in
modifying this relationship.
Table 5. Associations between high affinity
{ SSRI use and RV measures in limited and adjusted models, stratified by sex for RV
mass and RVEDV.
Beta (95% CI) P value
Men
Beta (95% CI) P value
Women
Beta (95%CI) P value
RVSV, mL
Limited* 2.59 (0.18–4.99) 0.04 – – – –
Adjusted{ 2.85 (0.47–5.24) 0.02 – – – –
RVEF, %
Limited 20.08 (20.99–0.83) 0.86 – – – –
Adjusted 20.25 (21.15–0.66) 0.60 – – – –
Adjusted + LVEF 20.26 (21.09–0.58) 0.55 – – – –
RV mass, g
Limited – – 1.15 (0.14–2.17) 0.03 0.15 (20.37–0.67) 0.57
Adjusted – – 1.21 (0.19–2.23) 0.02 0.25 (20.27–0.77) 0.35
Adjusted + LV mass – – 1.30 (0.35–2.24) 0.01 0.20 (20.30–0.69) 0.43
RVEDV, mL
Limited – – 5.31 (21.45–12.07) 0.12 2.83 (20.41–6.07) 0.09
Adjusted – – 5.94 (20.81–12.70) 0.09 3.67 (0.43–6.90) 0.03
Adjusted + LVEDV – – 7.78 (2.77–12.78) ,0.01 1.80 (20.62–4.21) 0.14
RVESV, mL
Limited 0.88 (20.73–2.49) 0.29 – – – –
Adjusted 1.28 (20.33–2.90) 0.12 – – – –
Adjusted + LVESV 1.19 (20.26–2.64) 0.11 – – – –
*Adjusted for age, sex, race/ethnicity, height, weight, and level of education.
{Adjusted for age, sex, race/ethnicity, height, weight, level of education, depression (Center for Epidemiologic Studies Depression-Scale (CES-D) $16), smoking (status
and pack-years), hypertension, systolic and diastolic blood pressure, cholesterol, low-density lipoprotein levels, triglycerides, and statin use.
{Fluoxetine, fluvoxamine, paroxetine, and sertraline.
doi:10.1371/journal.pone.0030480.t005
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